Overview
Zheyuan Technology is an AI pharmaceutical research and development solutions provider
Funding
Amounts as reported; USD estimates shown only when they matchListed 3 funding records. Latest funding: RMB 200M (Series A+), Mar 12, 2026.
1 listed record lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Mar 12, 2026 | RMB 200M ≈ $28.6M · Series A+ | 中科创星, 圣湘生物, 圣维荣泉, 张江科投 | No source link |
Evidence Phil Rivers raises RMB 200 million in Series A+ financingOn 2026-03-12, according to Xiniu Data, Phil Rivers completed Series A+ financing, raising RMB 200 million. Investors were Shengxiang Biotechnology, Shengweirongquan, Zhangjiangketou, Zhongkechuangxing. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Dec 12, 2024 | Undisclosed · Strategic | 拓海鸿方 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Jun 15, 2022 | RMB 100M ≈ $14.3M · Series A | 博行资本, 泰雅资本, 海金格医药, 诺禾致源 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 3 valuation records.
No chartable valuation estimates yet.
3 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Mar 12, 2026 | — · Series A+ | 中科创星, 圣湘生物, 圣维荣泉, 张江科投 | No source link |
Evidence Phil Rivers raises RMB 200 million in Series A+ financingOn 2026-03-12, according to Xiniu Data, Phil Rivers completed Series A+ financing, raising RMB 200 million. Investors were Shengxiang Biotechnology, Shengweirongquan, Zhangjiangketou, Zhongkechuangxing. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Dec 12, 2024 | — · Strategic | 拓海鸿方 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Jun 15, 2022 | — · Series A | 博行资本, 泰雅资本, 海金格医药, 诺禾致源 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
More Industry apps companies
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
AI医药研发解决方案提供商 哲源科技是一家AI医药研发解决方案提供商